IRVINE, Calif.–(BUSINESS WIRE<\/a>)–Masimo<\/a> (NASDAQ: MASI) announced today the release of MX-7\u2122, its latest and most advanced rainbow SET\u00ae<\/sup> board. Designed for integration into the more than 200 multi-parameter monitors available from its more than 90 original equipment manufacturing (OEM) partners, MX-7 has the ability to support all 13 of Masimo\u2019s SET\u00ae<\/sup> pulse oximetry and rainbow\u00ae<\/sup> Pulse CO-Oximetry measurements in an advanced module re-engineered to reduce power needs.\n<\/p>\n This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210719005242\/en\/<\/a><\/p>\n Masimo MX-7\u2122 rainbow SET\u00ae Technology Board (Photo: Business Wire)<\/p>\n<\/div>\n \nThe MX-7 adds to Masimo\u2019s growing portfolio of technology boards used both in its own patient monitors and also available to its OEM partners. MX-7 builds on the current MSX\u2122 low-power SET\u00ae<\/sup> board and MX-5\u2122 rainbow\u00ae<\/sup> board by offering more efficient power utilization, scaling its power draw based upon the combination of rainbow SET\u00ae<\/sup> parameters being monitored to permit even longer battery run times.\n<\/p>\n \nThe MX-7 offers the full suite of Masimo\u2019s advanced noninvasive SET\u00ae<\/sup> and rainbow\u00ae<\/sup> parameters. Masimo SET\u00ae<\/sup> pulse oximetry has been clinically proven to help care teams enhance patient safety and improve patient outcomes; in fact, more than 100 independent and objective studies have shown that Masimo SET\u00ae<\/sup> outperforms other pulse oximetry technologies during motion and low perfusion conditions, providing clinicians with increased sensitivity and specificity to make critical care decisions.1<\/sup> SET\u00ae<\/sup> has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2<\/sup> improve CCHD screening in newborns,3<\/sup> and, when used for continuous monitoring with Masimo Patient SafetyNet\u2122 in post-surgical wards, reduce deaths due to opioid overdose and reduce rapid response team activations, ICU transfers, and costs.4-7<\/sup><\/p>\n \nBy leveraging additional wavelengths of light and breakthrough signal processing, Masimo rainbow\u00ae<\/sup> technology allows clinicians to noninvasively and continuously monitor multiple advanced parameters that previously could only be measured using invasive techniques.\n<\/p>\n \nAmong other rainbow SET\u00ae<\/sup> parameters, MX-7 offers:\n<\/p>\n \nJoe Kiani, Founder and CEO of Masimo, said, \u201cThe MX-7 board represents that ongoing drive for innovation and improvement, making sure that our full suite of cutting edge SET\u00ae<\/sup> and rainbow\u00ae<\/sup> measurements are universally available to all of our customers.\u201d\n<\/p>\n \nORi has not received FDA 510(k) clearance and is not available for sale in the United States.\n<\/p>\n @Masimo<\/a> | #Masimo\n<\/p>\n About Masimo<\/b><\/p>\n \nMasimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET\u00ae<\/sup> Measure-through Motion and Low Perfusion\u2122 pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1<\/sup> Masimo SET\u00ae<\/sup> has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2<\/sup> improve CCHD screening in newborns,3 <\/sup>and, when used for continuous monitoring with Masimo Patient SafetyNet\u2122 in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7 <\/sup>Masimo SET\u00ae<\/sup> is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,15<\/sup> and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2020-21 U.S. News and World Report<\/i> Best Hospitals Honor Roll.16<\/sup> Masimo continues to refine SET\u00ae<\/sup> and in 2018, announced that SpO2<\/sub> accuracy on RD SET\u00ae<\/sup> sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2<\/sub> values they rely on accurately reflect a patient\u2019s physiological status. In 2005, Masimo introduced rainbow\u00ae<\/sup> Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb\u00ae<\/sup>), oxygen content (SpOC\u2122), carboxyhemoglobin (SpCO\u00ae<\/sup>), methemoglobin (SpMet\u00ae<\/sup>), Pleth Variability Index (PVi\u00ae<\/sup>), RPVi\u2122 (rainbow\u00ae<\/sup> PVi), and Oxygen Reserve Index (ORi\u2122). In 2013, Masimo introduced the Root\u00ae<\/sup> Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine\u00ae<\/sup> Brain Function Monitoring, O3\u00ae<\/sup> Regional Oximetry, and ISA\u2122 Capnography with NomoLine\u00ae<\/sup> sampling lines. Masimo\u2019s family of continuous and spot-check monitoring Pulse CO-Oximeters\u00ae<\/sup> includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7\u00ae<\/sup> and Radius PPG\u2122, portable devices like Rad-67\u00ae<\/sup>, fingertip pulse oximeters like MightySat\u00ae<\/sup> Rx, and devices available for use both in the hospital and at home, such as Rad-97\u00ae<\/sup>. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation\u2122 platform, and include Iris\u00ae<\/sup> Gateway, iSirona\u2122, Patient SafetyNet, Replica\u2122, Halo ION\u2122, UniView\u00ae<\/sup>, UniView :60\u2122, and Masimo SafetyNet\u2122. Additional information about Masimo and its products may be found at www.masimo.com<\/a>. Published clinical studies on Masimo products can be found at www.masimo.com\/evidence\/featured-studies\/feature\/<\/a>.\n<\/p>\n \nORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.\n<\/p>\n References<\/b><\/p>\n Forward-Looking Statements <\/strong><\/p>\n \nThis press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo MX-7\u2122<\/sup> and rainbow SET\u00ae<\/sup>. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including Masimo MX-7 and rainbow SET\u00ae<\/sup>, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov<\/a>. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210719005242\/en\/<\/a><\/span><\/p>\n Masimo KEYWORDS:<\/b> United States North America California<\/p>\n INDUSTRY KEYWORDS:<\/b> Medical Devices Health Hospitals Surgery Practice Management General Health<\/p>\n![\"Masimo](\"https:\/\/mms.businesswire.com\/media\/20210719005242\/en\/892171\/4\/MX-7_webready.jpg\")
<\/p>\n\n
\n
<\/p>\n
\n<\/i>
Evan Lamb
\n
949-396-3376
\n
elamb@masimo.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210719005242\/en\/473630\/3\/Masimo_logo_black_flat_nomark.jpg\"){kind=logo}
<\/td>\n<\/tr>\n![\"Photo\"](\"https:\/\/mms.businesswire.com\/media\/20210719005242\/en\/892171\/3\/MX-7_viewimage.jpg\")
<\/td>\n<\/tr>\n